CSN and CAVA: variant annotation tools for rapid, robust next-generation sequencing analysis in the clinical setting

Genome Medicine
Márton MünzNazneen Rahman


Next-generation sequencing (NGS) offers unprecedented opportunities to expand clinical genomics. It also presents challenges with respect to integration with data from other sequencing methods and historical data. Provision of consistent, clinically applicable variant annotation of NGS data has proved difficult, particularly of indels, an important variant class in clinical genomics. Annotation in relation to a reference genome sequence, the DNA strand of coding transcripts and potential alternative variant representations has not been well addressed. Here we present tools that address these challenges to provide rapid, standardized, clinically appropriate annotation of NGS data in line with existing clinical standards. We developed a clinical sequencing nomenclature (CSN), a fixed variant annotation consistent with the principles of the Human Genome Variation Society (HGVS) guidelines, optimized for automated variant annotation of NGS data. To deliver high-throughput CSN annotation we created CAVA (Clinical Annotation of VAriants), a fast, lightweight tool designed for easy incorporation into NGS pipelines. CAVA allows transcript specification, appropriately accommodates the strand of a gene transcript and flags variants with ...Continue Reading


Jan 11, 2000·Nucleic Acids Research·Stephen T SherryK Sirotkin
Aug 2, 2001·Human Genetics·Johan T den Dunnen, S E Antonarakis
Oct 22, 2004·Nature·International Human Genome Sequencing Consortium
May 17, 2005·Genome Biology·Karen EilbeckMichael Ashburner
Jun 10, 2009·Bioinformatics·Heng Li1000 Genome Project Data Processing Subgroup
Jun 22, 2010·Bioinformatics·William McLarenFiona Cunningham
Jul 6, 2010·Nucleic Acids Research·Kai WangHakon Hakonarson
Oct 29, 2010·Genome Research·Gerton Lunter, Martin Goodson
Feb 11, 2011·Nature·Eric D GreenNational Human Genome Research Institute
Jun 10, 2011·Bioinformatics·Petr Danecek1000 Genomes Project Analysis Group
Jan 17, 2014·Nature·Nazneen Rahman
Aug 8, 2014·Clinical Medicine : Journal of the Royal College of Physicians of London·Nazneen Rahman


Jan 11, 2016·American Journal of Human Genetics·Tychele N TurnerEvan E Eichler
Aug 4, 2016·Scientific Reports·Elise RuarkNazneen Rahman
May 30, 2017·Nature Genetics·Shawn YostNazneen Rahman
Mar 1, 2017·BMC Bioinformatics·Sarah SandmannMartin Dugas
Oct 13, 2018·Human Mutation·Piotr PawliczekClinical Genome (ClinGen) Resource
May 20, 2020·Journal of the National Cancer Institute·Julie R PalmerFergus J Couch
Apr 11, 2017·PeerJ·Miika J AhdesmäkiJustin H Johnson
Jun 9, 2018·Wellcome Open Research·Márton MünzNazneen Rahman
Aug 25, 2020·JCO Precision Oncology·Marco MatejcicChristopher A Haiman
Nov 7, 2017·Frontiers in Microbiology·Camilla SekseJianxin Shi
Jun 21, 2018·JAMA : the Journal of the American Medical Association·Chunling HuFergus J Couch
Oct 9, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Siddhartha YadavRobert R McWilliams

Related Concepts

BRCA1-IRIS protein, human
BRCA2 protein, human
Sequence Determinations, DNA
Computational Molecular Biology
BRCA1 Protein
BRCA2 Protein
Molecular Sequence Annotation
High-Throughput Nucleotide Sequencing
Clinical Trials

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.